<DOC>
	<DOCNO>NCT00086970</DOCNO>
	<brief_summary>This randomized phase I trial study side effect best dose O ( 6 ) -benzylguanine give together ifosfamide see well work compare ifosfamide alone treat patient unresectable metastatic solid tumor . Drugs use chemotherapy , ifosfamide O ( 6 ) -benzylguanine , work different way stop tumor cell divide stop grow die . Combining ifosfamide O ( 6 ) -benzylguanine may kill tumor cell</brief_summary>
	<brief_title>Ifosfamide With Without O ( 6 ) -Benzylguanine Treating Patients With Unresectable , Metastatic Solid Tumors</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine maximum tolerate dose O6-benzylguanine administered standard high-dose ifosfamide patient unresectable , metastatic solid tumor . II . Determine whether O6-benzylguanine enhance ifosfamide-mediated myelosuppression patient treat regimen . III . Determine relationship O6-benzylguanine dose intra-individual variability degree myelosuppression patient treat regimen . IV . Determine safety toxicity regimen patient . SECONDARY OBJECTIVES : I . Determine effect O6-benzylguanine pharmacodynamic endpoint , include apoptosis DNA damage , patient treat regimen . II . Determine pharmacokinetics O6-benzylguanine major metabolite , 8-oxoBG , patient treat regimen . OUTLINE : This randomize , open-label , multicenter , dose-escalation study O6-benzylguanine . Course 1 : All patient receive high-dose ifosfamide IV continuously 72 hour day 1-3 . Course 2 : Patients randomize 1 2 treatment arm . Arm I : Patients receive high-dose ifosfamide course 1 . Arm II : Patients receive bolus dose O6-benzylguanine ( BG ) IV 1 hour day 1 follow BG IV continuously high-dose ifosfamide IV continuously 72 hour day 1-3 . Cohorts 6-12 patient receive escalate dos BG ( administer bolus continuous infusion course 2 ) maximum tolerate dose ( MTD ) determine . The MTD define dose precede 3 6 4 12 patient experience dose-limiting toxicity . Course 3 subsequent course : All patient receive BG ( MTD determine course 2 , arm II ) high-dose ifosfamide course 2 , arm II . In course , patient also receive filgrastim ( G-CSF ) begin day 5 continue blood count recover . In course arm , treatment repeat every 21 day absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>O ( 6 ) -benzylguanine</mesh_term>
	<criteria>Histologically confirm solid tumor Unresectable , metastatic disease No primary tumor Eligible highdose ifosfamidebased therapy No known brain metastasis Performance status ECOG 01 Performance status Karnofsky 70100 % More 12 week Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 AST ALT ≤ 2.5 time upper limit normal Bilirubin normal Creatinine normal Creatinine clearance ≥ 60 mL/min No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 4 week study participation No history allergic reaction attribute compound similar chemical biological composition O6benzylguanine study agents No concurrent uncontrolled illness No active ongoing infection No psychiatric illness social situation would preclude study compliance More 24 hour since prior colonystimulating factor ( filgrastim [ GCSF ] sargramostim [ GMCSF ] ) No prior hematopoietic stem cell transplantation No concurrent pegfilgrastim No concurrent immunotherapy More 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover No concurrent chemotherapy No concurrent hormonal therapy More 4 week since prior radiotherapy recover No concurrent therapeutic radiotherapy More 4 week since prior anticancer therapy No 2 prior cytotoxic regimens No concurrent combination antiretroviral therapy HIVpositive patient No concurrent anticancer agent therapies No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>